Draft:Andrew M Wardley

• Comment: Sections of this are totally unsourced, which isn't permitted, and frankly most of this is unencyclopedic biographic details that don't belong on Wikipedia. Qcne (talk) 14:18, 26 September 2024 (UTC)

---

Andrew Wardley
Born	(1966-01-29) January 29, 1966 Preston, Lancashire
Nationality	British
Education	MB. ChB. (Hons), MRCP(UK), MSc, MD, CCST, FRCP, FACP(UK)
Alma mater	The Association of Cancer Physicians, University of Leeds, Royal College of Physicians, Health Education England Yorkshire Postgraduate Deanery, Heath Education England North West Postgraduate Deanery, The University of Manchester, Grays Inn
Occupation	Medical Oncologist
Known for	Oncology, Cancer Research, Pioneering National & International Clinical Trials, Breast Cancer Treatments, Medical Education, Integrated Care Systems, NHS Service Design, Oncology Innovation, Drug Development, Translational Research, Clinical Negligence Law, Executive Leadership
Medical career
Field	Cancer Medicine and Clinical Research

Andrew Wardley born 29 January 1966 is a medical professor, clinical entrepreneur, CEO, and Founder of Cancer Services. He has an international reputation for breast cancer, clinical research, and medical education and leadership. He is a leader in national and international trials, pioneering major advances in breast cancer to improve outcomes for patients.

Early life and education

Wardley was born in Preston, Lancashire and raised by a single mother in a conservative Church of England community. He attended Baines School Poulton-le-Fylde where he excelled at sports and academic subjects. He was the captain of the football team which won the Blackpool schools cup in 1981.

In 1989 Wardley graduated with honors in Bachelor of Medicine and Bachelor of Surgery from the University of Manchester, and Diploma of MRCP(UK) Medicine from the Royal College of Physicians in 1993. In 1993 he specialised in Medical Oncology, training in both Manchester and Leeds, completing a MSc in Oncology and Cancer Biology and a Research Doctorate (MD) at the University of Manchester simultaneously completed Higher Specialist Training in Medical Oncology at HEE Postgraduate Deanery and University of Leeds where he was the first of "Calman-Hine trainees" with Professor Peter Selby, co-author of Calman Hine Report. He received a Certificate of Completion of Higher Specialist Training in Medical Oncology (CCST) from the Joint Royal Colleges of Physicians Training Board.

In 2002, the European Society for Medical Oncology elected him as a member, and in 2004, the American Society of Clinical Oncology also elected him as a member. In 2005 he became a Fellow of the Royal College of Physicians of London. In 2023 he became a Fellow of Association of Cancer Physicians for outstanding contributions to breast cancer research and Medical Oncology.

He has completed the NHS Leadership Academy 2013 and Improvement Science for Academics training, where the team he led won the NCIN 2015 poster prize for developing an electronic tool to improve trial recruitment. In 2023 he pursued a Masters in Law to continue to sit the Bar in 2025.

Career

In 1989, Wardley started his career as a House Physician at Salford Royal Hospital where he worked for Dr. Annie Holmes. In 1990 as House Surgeon at Leigh Infirmary he provided medical support for the surgical team. After completing his house jobs, he became a Senior House Officer at Royal Liverpool Hospital intent on a career in renal medicine. In 1991 he was a Senior House Officer (Haematology) at The Christie NHS Foundation Trust.In 1992 as a medical registrar at Trafford General Hospital he ran the acute hospital at night and on weekends supervising ITU and CCU. In 1993 his higher specialist training in Medical Oncology began, as a Clinical Lecturer at the University of Manchester (Honorary Registrar) supervising junior medical staff in the Adult Leukemia Unit and Acute Oncology ward. From 1995 to 1997 he worked in Prof Christopher Potten lab where he developed a model of oral mucositis which has been used to develop effective treatments for this debilitating side-effect of cancer treatment and described the clinical course of oral mucositis in hematological transplant patients.

In 1997 his first point on this rotation was as the first Specialist Registrar at Huddersfield Royal Infirmary He then worked, from 1998 to 2000 at the ICRF Department of Medical Oncology St. James University Hospital where he learned breast cancer treatment with Professor Timothy Perren and basics of palliative care medicine. In December 2000 he completed his specialist training in Medical Oncology and received a Certificate of Completion. He then secured a consultant post in breast cancer and attended his first San Antonio Breast Cancer Symposium. He conceived a holistic patient-centered, research driven model of care at this time.

In January 2001 he started as a Medical Oncology Consultant at the Christie Hospital, South Manchester University Hospital and WWL NHS Foundation Trust. By 2002 Wardley established the University Hospital of South Manchester home of the largest breast unit in the UK, and Wigan hospital as systemic anti-cancer therapy research sites and a de facto network. South Manchester Breast Unit became a major contributor to endocrine therapy trials in breast cancer, including BIG1-98, and topped recruitment. Wardley worked with commissioners and created innovative models of care to ensure that treatments developed in trials were implemented into service. He later implemented these models across all systemic anti-cancer therapies in Greater Manchester & Cheshire. He has been instrumental in the development of all the categories of breast cancer systemic anti-cancer therapy since 2001, improving outcomes for patients with breast cancer. In 2005 he secured £9 million to implement a service for adjuvant trastuzumab (Herceptin™) in Greater Manchester & Cheshire before NICE approval including ensuring the development of a cardiac network for essential monitoring. He has regularly been a clinical expert advisor to NICE for breast cancer drugs technology appraisals and diagnostic appraisals. In 2016 Wardley secured funding for Greater Manchester Adjuvant Bisphosphonate service and implemented this. Both models ensure equity of access across the population for important treatments to increase survival.

Wardley has been key in the development of cancer research across the world and the development of Medical Oncology and Cancer Research in Manchester and UK. Wardley's work led to the formation of the AstraZeneca Manchester University-Christie Alliance (precursor to Manchester Cancer Research Centre) in 2004. Wardley was co-founder of Manchester Breast Centre in 2005 bringing together clinical and laboratory researchers to advance knowledge, understanding, and treatment for breast cancer where he led Breast Medical Oncology research as Principal Investigator in 2005–2021. He led the establishment and funding of the Manchester Academic Health Science Centre earning a Clinical Chair for his significant research contribution. Furthermore, he held an Honorary Clinical Chair at The University of Manchester. Wardley connected Manchester with the National Cancer Research Institute [NCRI] Breast Cancer Clinical Studies Group, and during the period 2003–2009, was key to the development of most NCRI breast cancer systemic anti-cancer therapy SACT trials. He established Greater Manchester as the major centre in the UK for the delivery of cancer trials. Before this, Manchester contributed very few patients to national breast cancer trials. He was Chief Investigator of CHAT, tAnGo (joint), Lead Investigator of PERSEPHONE; UK Chief Investigator of many international trials, including the first National Translational Research Institute breast cancer trial; Co-applicant PERSEPHONE, EPHOS-B and a member of Elderly Breast Cancer Working Group and Advanced Breast Cancer Open Working Parties. From 2014 to 2021 Wardley led the Early Breast Cancer sub-Group for SACT at NCRI. He conceived and led HER-2-RADiCAL to NIHR grant funding as the natural successor to PERSPHONE. In 2020 he assumed the role of Chair for NCRI Breast Research Group and in 2022 Wardley was appointed as Chair for WG2 metastatic breast cancer for NCRI. He was a Breast Cancer Faculty at ESMO.

In 2012 the Clinical Research Facility at The Christie NHS Foundation Trust appointed Wardley as the Clinical Director where he successfully secured NIHR grant funding (£4.5M) from 2012 to 2017. In 2016, Wardley and the directors of three other NIHR Clinical Research Facilities in Manchester created the NIHR Manchester Clinical Research Facility, securing a £12.5 million NIHR grant. He secured funding for research activity in the Integrated Procedures Unit and the rebuilding of the NIHR Manchester Clinical Research Facility at the Christie hospital NHS Foundation Trust (£3.1M) to become the first CRF capable of delivering ATIMP trials for solid cancers. He was the lead for cancer experimental medicine for the largest and most comprehensive CRF in the UK. From 2014 to 2019, Wardley was Clinical Lead for Cancer Research at NIHR Clinical Research Network Greater Manchester and established SACT trials across their network. He developed the Wigan site to be Registration trial compliant, and his team won the Team of the Year Award. He also earned an NIHR lead commercial investigator award, and during the period from 2015 to 2021 he actively participated as a member of the National Early Phase cancer research group at NIHR.

In 2012 he was the Clinical Director of Medical Oncology at The Christie NHS Foundation Trust, and Deputy Director/Acting Director at (Greater) Manchester Cancer which he helped to create after the dissolution of cancer networks. He secured funding from Greater Manchester Cancer Network and started the implementation of acute oncology services. Wardley led the development of systemic anti-cancer therapy (SACT) services, 2011-21 and the development of Medical Oncology in district general hospitals, SACT delivery in patients' homes, General Practice sites, and hospices. From 2015 to 2019 Wardley held the position of Director of Systemic Anti-Cancer Therapy at the Greater Manchester Cancer Alliance, where he devised and authored the strategy for SACT, as well as the research strategy for Greater Manchester Plan 2015. Wardley led the implementation and development of the first electronic SACT prescribing system in Greater Manchester & Cheshire and his team RAPTOR-D won the Improvement Science for Academics program poster prize for improving patient care by developing an electronic patient record tool to identify patients for 2 early phase breast clinical trials. His work at Greater Manchester also attracted interest from SAP and Flatiron.

In 2018 Wardley led a Joint Working Program with IQVIA funded by Novartis and Devolution Manchester, to investigate inequalities of access to secondary breast cancer treatment in Greater Manchester. This project, presented at HSJ Cancer Forum and Greater Manchester Cancer Conference 2019, used multiple disparate data sources to investigate variation in treatment pathways and medicines use across Greater Manchester, including IQVIA's unique Hospital Pharmacy Audit data provided insight into the variation in prescribing and access to standard breast cancer treatments across Greater Manchester.

From 2013 to 2021 he was a key contributor to the Chemotherapy Clinical Reference Group at NHS England a key advisor on breast cancer drugs, service design, and introduced 2 cQUINs to NHSE. From 2013 to 2021 he was in the Chemotherapy Clinical Information Group at Public Health England helping with developing knowledge from the systemic anti-cancer therapy dataset, including 30-data mortality publications. The University of Manchester recognised his contributions to research and cancer medicine in 2016 by awarding him an Honorary Clinical Chair. He also received an appointment to a Manchester Academic Health Science Centre Chair where he led in delivering research and innovation within the NHS. Developing his work to tackle inequalities of access to experimental medicine and secondary breast cancer care, he developed a Health Inequalities program, funding 2 Ph.D. students, conceiving and creating the first Nurse Consultant Advanced Nurse Practitioner post in cancer research in the UK. From 2001 to 2021 he was a Medical Educator at Health Education England North West (East) Deanery and an Honorary Senior Lecturer, then Chair at the University of Manchester.

From 2008 to 2011 Wardley was Training Programme Director for Medical Oncology at Northwest (East) Deanery, an active member of the STC for Medical Oncology (2001–2011), and Co-author of Medical Oncology National Curriculum in 2008. He has led 20 years of continuous improvement in Breast Medical Oncology of International standing, including ESMO Oncology Breast Cancer Faculty 2008-2021, and ESO-MBC Task Force for the first Advanced Breast Cancer Guidelines Conference, conceived & developed the Health Inequalities program, supervised many Ph.D. students including, funding & supervising Clinician Scientist positions and played an active role in teaching undergraduates and supervising work experience students leading to international publications/presentations, as well as being editor and reviewer several journals. He has been a primary driver and instigator of Advanced non-medical Practitioner Roles, including Advance Nurse Practitioner (ANPs) in clinical trials, Systemic Anti-Cancer Therapies (SACT) services, Breast cancer Nurse Clinicians, and Advanced Pharmacy Prescribers. Between 2019–2021, he was a CPD Approver at the Royal College of Physicians

In 2020 Wardley supported a group of staff raising [[Public Interest Disclosure disclosures against The Christie NHS Foundation Trust. Due to the circumstances Wardley had no choice but to leave the NHS in the same year. His courage and sacrifice in making protected disclosures led to a rapid review conducted by NHS England in October 2021 which was published in January 2022 Since then Wardley has continued his efforts of justice, which has led the Trust to be downgraded in March 2023 by the Care Quality Commission

Since March 2022 Wardley has continued his efforts to improve access to cancer treatments by creating the first global medical second opinion service accessible to patients globally. As a self employed management consultant he was afforded the opportunity to be the Global Clinical Head for breast cancer at AstraZeneca to bring clinical expertise to drug development for Camizestrant and Capivasertib. He designed the early breast cancer strategy and trials for Camizestrant, including biomarker and translational research, and connected AstraZeneca to international breast cancer research collaboratives and Key Opinion Leaders in breast cancer and biotechnology. Wardley continues to play a crucial role in developing the Medical Oncology Specialty in the UK through The Association of Cancer Physicians a learned society within the Royal College of Physicians who appointed him Chair in April 2023 Wardley passion now lies in justice for whistle-blowers as he embarks in his steps to become a Barrister.

Personal life

An only child, Wardley spent his early life with his grandparents. Wardley is the father of a daughter and lives in his family home in West Yorkshire. He continues to play 5-a-side football with colleagues with whom he has played for 30 years, has taken up yoga, and loves his dogs, Jake and Charlie. As a devoted Christian and authentic leader, he serves his community participating in initiatives supporting those with mental health. Wardley associates himself as being a Neurodivergent since his diagnosis in 2022.

Wardley is a cancer survivor and understands the patient journey. In 2009, Wardley received a diagnosis of adult T-cell acute lymphoblastic leukemia. This was a relief as doctors had previously misdiagnosed him with Mantle cell lymphoma. He received an allogeneic stem-cell transplant in December 2009. This firsthand experience of being a cancer patient increased his passion for equitable access to cancer treatments during his career in medicine.

Awards

Wardley has been the recipient of several awards during his career;

1. 2005 selected to be part of AstraZeneca Future Forum on Breast Cancer
2. 2012 Bronze Award–ACCEA
3. 2017 Silver Award–ACCEA
4. 2015 NIHR Lead Commercial Investigator Award
5. 2016 Honorary Chair University of Manchester
6. Presentations at major international conferences including ASCO, ESMO, SABCS, EBCC.
7. Joint Committee on Higher Medical Training Innovative Medical Oncology Curriculum and Assessment & Joint leader of breast cancer sub-group 2008.
8. Speciality Editor in Medical Oncology for The Breast.
9. Associate Editor: Advances in Breast Cancer, New Directions in Endocrine Treatment of breast cancer.
10. Editor Dana Farber Cancer Institute Breast cancer handbook

Publications

Wardley has authored over 300 publications in peer-reviewed journals.

Further reading

1. https://www.clinicaltrialsarena.com/features/ncri-closure-impact-uk-research-cancer/
2. https://www.nice.org.uk/Media/Default/Get-involved/Meetings-In-Public/Technology-appraisal-committee/2020/minutes-tac-a-24-mar-20.docx
3. https://www.england.nhs.uk/north-west/wp-content/uploads/sites/48/2022/02/Christie-Rapid-Review-FINAL.pdf
4. https://api.cqc.org.uk/public/v1/reports/c9c97858-1c34-47ce-8800-abd36a97a4e4?20230512070254
5. https://www.rcr.ac.uk/media/1dwmin0a/rcr-briefing-on-the-short-medium-term-solutions-for-supporting-the-sact-capacity-crisis.pdf
6. https://gmcancerorguk.wordpress.com/wp-content/uploads/2019/11/gmcc-2019-agenda-v4.pdf
7. https://assets.publishing.service.gov.uk/media/5a7d94d640f0b64fb735c448/PersonalStatement.pdf
8. https://cdn.evbuc.com/eventlogos/79471085/ukcrfprogramme-5.pdf